Sumatriptan is a selective 5-HT1D receptor agonist in cranial arteries.
The vascular 5-HT1D receptor is predominantly found in cranial blood vessels and is involved in vasoconstriction.
Dilation and/or oedema formation in these vessels is considered the underlying mechanism in migraine attacks.
Sumatriptan causes cranial vasoconstriction and inhibition of trigeminal nerve activity, which may contribute to its antimigraine action.
The clinical response begins at 30 minutes after administration. The recommended dose is 50 mg orally.
Migraine attacks vary in severity, both in same patient episodes as well among different people. In clinical trials, doses of 25 to 100 mg has been shown to be effective; the most usual doses are 50 mg and 100 mg.
Sumatriptan is effective in the acute treatment of migraine with and without aura.
Each tablet contains 100 mg of Sumatriptan.
Packages containing 2 and 6 tablets.